Budesonide/Formoterol Pressurized Metered-Dose Inhaler

Lyseng-Williamson, Katherine A.
July 2009
Drugs;2009, Vol. 69 Issue 11, p1459
Academic Journal
The corticosteroid budesonide and the rapid-onset, long-acting β2-adrenoceptor agonist formoterol have been combined into a single pressurized metered-dose inhaler (pMDI) for use in patients with chronic obstructive pulmonary disease (COPD). Well designed 6- and 12-month clinical trials, twice-daily budesonide/formoterol pMDI 320 μg/9 μg effectively improved lung function in patients with moderate to very severe COPD. The co-primary endpoints of adjusted mean morning predose forced expiratory volume in 1 second (FEV1) and 1-hour post-dose FEV1 improved from baseline to a significantly greater extent with twice-daily budesonide/formoterol pMDI 320 μ/9 μg than with twice-daily placebo, budesonide pMDI 320 μg and formoterol dry powder inhaler 9 μg. Budesonide/formoterol pMDI was also associated with improvements from baseline in other measures of lung function, COPD control (including the time to first COPD exacerbation in the 12-month trial), symptoms and health status. These improvements were significantly greater than those observed with placebo and, for some endpoints, monotherapy with the individual components. Budesonide/formoterol pMDI was well tolerated in clinical trials in patients with COPD. Its overall adverse event profile is consistent with the known tolerability profiles of formoterol and budesonide, and is generally similar to that with placebo.


Related Articles

  • Qualitative assessment of attributes and ease of use of the ELLIPTATM dry powder inhaler for delivery of maintenance therapy for asthma and COPD. Svedsater, Henrik; Dale, Peter; Garrill, Karl; Walker, Richard; Woepse, Mark W. // BMC Pulmonary Medicine;2013, Vol. 13 Issue 1, p1 

    Background Medications for respiratory disorders including asthma and chronic obstructive pulmonary disease (COPD) are typically delivered to the lung by means of a handheld inhaler. Patient preference for and ability to use the inhaler may influence their adherence to maintenance therapy, and...

  • Pharmacotherapy of Chronic Obstructive Pulmonary Disease: Focus on Arformoterol Tartrate. King, Paul T. // Clinical Medicine: Therapeutics;2009, Issue 1, p1321 

    Arformoterol tartrate is a newly developed long-acting ssβ2-agonist with both acute and prolonged bronchodilator effects. It is formed of 2 isomers (R,R/R,R) which distinguishes it from the more commonly used racemic formoterol (R,R/S,S). The active isomer is the (R,R) and in vitro...

  • Formoterol Oral Inhalation.  // AHFS Consumer Medication Information;Aug2020, p1 

    Formoterol is used to treat wheezing, shortness of breath, and breathing difficulties caused by asthma and chronic obstructive pulmonary disease (COPD; a group of lung diseases that includes chronic bronchitis and emphysema). It also is used to prevent breathing difficulties (bronchospasm)...

  • Review: long-acting inhaled therapies and pulmonary rehabilitation are effective in stable COPD.  // Evidence Based Medicine;Apr2008, Vol. 13 Issue 2, p56 

    REVIEW PROCESS Question: in patients with stable chronic obstructive pulmonary disease (COPD), are inhaled therapies and other interventions effective? Search methods: Medline and Cochrane Library (1966 to March 2007), Cochrane Database of Systematic Reviews of Effectiveness, reference lists,...

  • Tiotropium Respimat as safe as Handihaler.  // Reactions Weekly;9/28/2013, Issue 1471, p3 

    The article focuses on the Tiotropium Safety and Performance in Respimat (TIOSPIR) study as of September 2013 which revealed that tiotropium respimat had a similar safety profile to that of tiotropium handihaler taken once daily in patients with chronic obstructive pulmonary disease.

  • Clinic Roundup.  // BioWorld Today;11/17/2011, Vol. 22 Issue 224, p2 

    This section offers news briefs related to clinical trials as of November 2011. Almirall SA of Spain and Forest Laboratories Inc. of New York started a Phase III trial of a fixed-dose combination of aclidinium bromide and formoterol fumarate through the Genuair inhaler for chronic obstructive...

  • Preliminary Randomized Open Labeled Comparative Analysis of Efficacy & Safety of Inhaled Tiotropium and Tiotropium Plus Formoterol in COPD. Pukhta, Muzaffer Ahmad; Ashai, Zubair Ahmad; Shah, Mushtaq Ahmad; Abbas, Zaffar; Farhat, Samina; Mir, Shakeel Ahmad; Singh, Z.; Tandon, Vishal R. // JK Science;Jan-Mar2010, Vol. 12 Issue 1, p27 

    A randomized, open labeled comparative analysis for 2-week therapy of inhaled Tiotropium (T) (n=30) and Tiotropium plus Formoterol (TF) (n=30) once daily was carried in stable COPD patients. Objective parameters like lung functions (FEV1 and FVC), SBP, DBP, pulse and subjective parameters like...

  • Dual therapy for COPD produces better outcomes.  // GP: General Practitioner;2/17/2003, p14 

    Reports that treating Chronic Obstructive Pulmonary Disease (COPD) with both a long-acting beta-two agonist and a corticosteroid produces a better outcome than using either drugs alone. Improvement shown in COPD patients due to active treatments; Benefits observed in the combination therapy for...

  • Indacaterol (Arcapta) for COPD. SOKOL, RANDI; MAXTED, GEORGE // American Family Physician;8/15/2014, Vol. 90 Issue 4, p252 

    The article evaluates the Arcapta Neohaler inhaler or indacaterol, developed for treating chronic obstructive pulmonary disease (COPD).


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics